Galunisertib
Galunisertib is a selective, ATP-competitive ALK5 (TGF-betaRI) inhibitor that blocks TGF-beta-mediated SMAD2/3 phosphorylation, disrupting tumour immune evasion, angiogenesis, and stromal remodelling. TGF-beta is a master immunosuppressive cytokine in solid tumour microenvironments. Extensively studied in GBM, HCC, and pancreatic cancer combinations with checkpoint inhibitors.
Description
Scientific Overview: Galunisertib is a selective, ATP-competitive ALK5 (TGF-betaRI) inhibitor that blocks TGF-beta-mediated SMAD2/3 phosphorylation, disrupting tumour immune evasion, angiogenesis, and stromal remodelling. TGF-beta is a master immunosuppressive cytokine in solid tumour microenvironments. Extensively studied in GBM, HCC, and pancreatic cancer combinations with checkpoint inhibitors.
Mechanism of Action: TGF-betaR1 (ALK5) Inhibitor
Purity: ≥99% | Molecular Formula: C18H14N4O
For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.
Additional information
| Effect | TGF-betaR1 (ALK5) Inhibitor |
|---|---|
| Purity | ≥99% |
| Molecular Formula | C18H14N4O |
| CAS Number | 700874-71-1 |
